Home › Activist investors › Wynnefield Capital
Campaign activist. Positions and campaigns from Wynnefield Capital’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
| Company | Stake | Source | First disclosed | Last change | Since previous filing | Flags | Stated intent |
|---|---|---|---|---|---|---|---|
| Lifecore Biomedical, Inc. | 14.3%5,512,210 shares | Schedule 13D/A, filed Sep 29, 2026 | Sep 29, 2026 | Increased Sep 29, 2026 | ▼ 1.70 pts | New | Seeks changes or engagement |
| DLH Holdings Corp. | 25.40%3,681,421 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 28, 2026 | May 15, 2014 | — | 0.00 pts | — | 13F: none stated |
| Nature's Sunshine Products, Inc. | 14.28%2,473,686 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 23, 2026 | May 15, 2014 | — | ▲ 0.22 pts | — | 13F: none stated |
| Quest Resource Holding Corp | 13.3%2,734,349 shares | Schedule 13D, filed May 8, 2025 | May 8, 2025 | — | — | — | Seeks changes or engagement |
| TechPrecision Corporation | 4.29%433,605 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 6, 2026 | Nov 14, 2023 | — | ▼ 0.03 pts | — | 13F: none stated |
| Cadre Holdings, Inc. | 2.81%1,205,000 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 | Feb 14, 2022 | — | ▼ 0.01 pts | — | 13F: none stated |
Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.
Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.
“…Agreement (the "Support Agreement") with Lifecore, Inc., a Delaware corporation ("Parent"), and the Issuer in connection with the Agreement and Plan of Merger, dated as of September 27, 2026, among Parent, Hazel Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of Parent ("Merger Sub"), and the Issuer (the "Merger Agreement"). The Merger Agreement provides, among other things and subject to its terms and conditions, for the…”
Item 4 in the Schedule 13D/A filed Sep 29, 2026.
Summary of the filing Wynnefield Partners, an existing board-seat holder at Lifecore, signed a support agreement to vote its shares for the company's pending merger with Lifecore, Inc.
Quoted from the filing (item 4): “On September 27, 2026, the Wynnefield Reporting Persons entered into a Voting and Support Agreement (the "Support Agreement") with Lifecore, Inc., a Delaware corporation ("Parent"), and the Issuer in connection with the Agreement and Plan of Merger, dated as of September 27, 2026” Sep 29, 2026
“On May 7, 2025, the Wynnefield Reporting Persons entered into a Cooperation Agreement (the " Cooperation Agreement") with the Issuer. Pursuant to the terms of the Cooperation Agreement, the Board of Directors of the Issuer (the "Board") agreed to expand the size of the Board by one member and appoint Robert Lipstein (the "New Director") to the Board as a Class III…”
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Quest Resource Holding Corp | Settled (agreement with the company) | May 8, 2025 | May 8, 2025 | — | latest (2) | — |
| Lifecore Biomedical, Inc. | Settled (agreement with the company) | Jul 1, 2024 | Jul 1, 2024 | — | latest (1) | — |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
No proxy contest has gone to a vote since July 1, 2023.
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Quest Resource Holding Corp | Settlement | agreement with the company | May 8, 2025 | May 8, 2025 |
| Lifecore Biomedical, Inc. | Settlement | agreement with the company | Jul 1, 2024 | Jul 1, 2024 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 1 of 2 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
| Company | First 13D | To latest close | SPY same dates | 6 months after | 12 months after |
|---|---|---|---|---|---|
| Lifecore Biomedical, Inc. LFCR | Sep 29, 2026 | -2.9%Sep 29, 2026 – Nov 18, 2026 | -4.4% | not yet / no price | not yet / no price |
Prices: daily closes (Nasdaq), as stored by the site.
Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.
“Mr. Korenberg will be appointed as a member of the Audit Committee upon appointment to the Board immediately following the 2023 Annual Meeting.” 8-K, Jul 1, 2024
“Pursuant to the 22NW Cooperation Agreement, the 22NW Investor Group has agreed that during the pendency of the Standstill Period, the 22NW Investor Group will take certain actions, including to vote, or cause to be voted, all shares of Common Stock and Preferred Shares beneficially owned by each member of the 22NW Investor Group in favor of (a) each of the directors nominated by the Board and recommended by the Board in the election of directors (and not in favor of any other…” 8-K, Jul 1, 2024
Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Wynnefield Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.
| Holder | Form | Date | Stake |
|---|---|---|---|
| BlackRock, Inc. | Schedule 13G | Apr 27, 2026 | 5.0% |